

**Supplementary Table 1.** Clinicopathological characteristics of serous ovarian cancer cohort

<b>High grade serous ovarian carcinomas (n=147)</b>		
Age at Diagnosis (years)	Median (range)	61 (24-87)
Histological Grade	Grade 2	22
	Grade 3	125
FIGO stage	Stage II	3
	Stage III	136
	Stage IV	8
Residual disease after surgery	No	20
	Yes	81
	Unknown	46
ABCA1 immunoreactive score	Median (range)	9 (4-12)
	Patient number	n=99
	unstained/lost cores	48
ABCB1 immunoreactive score	Median (range)	3 (0-12)
	Patient number	n=144
	Lost cores	3
ABCB3 immunoreactive score	Median (range)	9 (0-12)
	Patient number	n=126
	Lost cores	21
ABCC2 immunoreactive score	Median (range)	12 (0-12)
	Patient number	n=143
	Lost cores	4
ABCG2 immunoreactive score	Median (range)	12 (0-12)
	Patient number	n=144
	Lost cores	3
<b>Treatment</b>	<b>Cisplatin/cyclophosphamide</b>	<b>53</b>
	<b>Carboplatin/paclitaxel</b>	<b>56</b>
	<b>Carboplatin alone</b>	<b>11</b>
	<b>Other chemotherapy</b>	<b>11</b>
	<b>No chemotherapy</b>	<b>7</b>
	<b>Unknown</b>	<b>9</b>
Recurrence	No	24
	Yes	108
	Unknown	15
Cause of Death	Ovarian cancer	92
	Other cause	14
	Alive	40
	Lost to follow-up	1
Residual Disease	Yes	81
	No	20
	Unknown	46